Celiac Research Partnership Builds Takeda’s GI Interests

Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.

More from Alimentary/Metabolic

More from Therapy Areas